Ex vivo Manufactured Neutrophils for Treatment of Neutropenia-A Process Economic Evaluation.

ABSTRACT: Neutropenia is a common side-effect of acute myeloid leukemia (AML) chemotherapy characterized by a critical drop in neutrophil blood concentration. Neutropenic patients are prone to infections, experience poorer clinical outcomes, and require expensive medical care. Although transfusions of donor neutrophils are a logical solution to neutropenia, this approach has not gained clinical traction, primarily due to challenges associated with obtaining sufficiently large numbers of neutrophils from donors whilst logistically managing their extremely short shelf-life. A protocol has been developed that produces clinical-scale quantities of neutrophils from hematopoietic stem and progenitor cells (HSPC) in 10 L single-use bioreactors (1). This strategy could be used to mass produce neutrophils an

SUBMITTER: Torres-Acosta MA 

PROVIDER: S-EPMC6405517 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature